ClinicalTrials.gg
RecruitingNCT07436429DCB-STEMIUpdated Feb 27, 2026

Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction

An observational study in Myocardial Infarction (MI), ST-Elevation Myocardial Infarction and STEMI, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Primary conditionST Elevation Myocardial InfarctionRegistry: Myocardial InfarctionReclassifiedWhy we changed it
Registry
Myocardial Infarction — the first condition term the registry derived for this study.
ClinicalTrials.gg
ST Elevation Myocardial Infarction
Why
  1. The study's listed conditions name ST Elevation Myocardial Infarction, a narrower term within Myocardial Infarction.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Medical University of Vienna · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in ST Elevation Myocardial Infarction with a site in Austria — 7 open to participants now, 9 under way, none of them phase 3. ST Elevation Myocardial Infarction · Austria.

Started
2026
with 2 others
Observational
9 of 23
5 open now
Registered
21st of 23
by date
Lead sponsor
5 of 23
Medical University of Vienna

Among the 23 studies in ST Elevation Myocardial Infarction with a site in Austria, this one is one of 3 that started in 2026, is one of 9 observational ones, and was the 21st registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

7 of the 23 studies in ST Elevation Myocardial Infarction with a site in Austria are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in ST Elevation Myocardial Infarction with a site in Austria, or all of them as a file.
02

Study summary

Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited.

The aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.

03

Conditions studied

  • Myocardial Infarction (MI)
  • ST-Elevation Myocardial Infarction
  • STEMI
  • STEMI (STE-ACS)
  • Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Keywords

  • Drug-coated balloon
  • Primary percutaneous coronary intervention
  • De novo coronary lesion
  • Limus-coated balloon
  • Paclitaxel-coated balloon
  • Net adverse clinical events
  • Bleeding Academic Research Consortium bleeding
  • ST-segment elevation myocardial infarction
  • Drug-Eluting Balloon
04

In context

ST Elevation Myocardial Infarction Reclassified

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

This study's planned enrollment of 300 is below the median of 340 across 298 observational studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.

Compared within ST Elevation Myocardial Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adult patients admitted with STEMI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All ST-elevation MI undergoing Primary PCI

Exclusion criteria

Exclusion Criteria:

  • In-stent culprit lesion
  • to antiplatelets
  • Stent implantation within 3 months before enrollment
  • Cardiac arrest, intubation, or cardiogenic shock
  • Life-expectancy less than one year
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Adult patients admitted with STEMI (symptom onset within 48 hours prior to the procedure)

    Device: Drug-Coated Balloon

Interventions

  • DeviceDrug-Coated Balloon

    Provisional DCB-based pPCI for a de novo coronary

    Also known as: Drug-Eluting Balloon, DCB, DEB

07

What researchers measure

Primary outcomes

  1. Net adverse clinical events (NACE)

    Composite of :Device success, Procedural success, Angiographic success diameter stenosis \<40% by visual estimation and TIMI flow grade ≥2, Target vessel dissection ≥ type C, Bailout stenting

    Time frame: From January 2014 to April 2026

Secondary outcomes

  1. Individual NACE components

    Time frame: Jenuary 2014 to April 2026

  2. Any Bleeding

    Any bleeding classified according to the Bleeding Academic Research Consortium (BARC) criteria.

    Time frame: January 2014- April 2026

  3. Target Vessel Failure (TVF)

    Composite of cardiovascular death, target vessel myocardial infarction, or target vessel revascularization, according to Academic Research Consortium drug-coated balloon consensus definitions.

    Time frame: January 2014-April 2026

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jul 2026, 5 months after the start.

Of 122 non-industry observational studies under ST Elevation Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 107. This study's planned 5 months is below that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 21 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Feb 27, 2026
StartActual
Feb 8, 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 1, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07436429
Responsible party
Rayyan Hemetsberger (Ap. Prof. Priv.-Doz., Medical University of Vienna) — Principal investigator
First posted
Feb 27, 2026
Start date
Feb 8, 2026
Primary completion
Jul 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Riccardo Terzi, MD, BSc
Contact
riccardo.terzi1@gmail.com
+393312127467
Rayyan Hemetsberger, MD
principal investigator · Universitatsklinikum AKH wien
Mohammad Abdelghani, MD, PhD
principal investigator · Sohar Hospital, Sohar, Oman

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion